Through its new partnership with Antibodies Incorporated, Aves now offers highly-cited primary antibodies from Neuromab.

NeuroMab Logo

In response to the growing epidemic of poorly characterized antibodies, the NIH set out in 2005 to create a collection of painstakingly-validated antibodies for the neuroscience community. These antibodies were developed by the NIH-funded, UC Davis-based NeuroMab facility, and Antibodies Incorporated was selected as the production and distribution partner for the initiative. Since its inception in 2005, the project has yielded nearly 500 antibodies, many of them knockout-validated on mouse brain.

Most NeuroMab antibodies are sold either in TC Supernatant or Purified forms:

  • TC Supernatant
    Hybridoma tissue-culture supernatant (5mL) generally containing 10-50 ug/mL monoclonal antibody (clone-dependent) can be a very economical choice.  Supernatant is suitable for most applications including Western Blot, immunocytochemistry, immunohistochemistry, etc. For applications requiring higher antibody concentration or purity (such as immunoprecipitation, microinjection, or conjugation) it is recommended that you purchase the purified form.
  • Purified
    Produced by in vitro bioreactor culture of hybridoma lines followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody at 1mg/mL.

You can find more information about these antibodies, including publication citations, at the UC Davis NeuroMab facility’s website.